Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
Evonik Industries AG (EVK.DE)
Essen, DE
Evonik Industries AG operates primarily in the specialized chemicals market. Its business activities are structured across five principal divisions: Specialty Additives, Nutrition & Care, Smart Materials, Performance Materials, and Technology & Infrastructure. The Specialty Additives segment is responsible for delivering essential ingredients such as polyurethane additives, modified silicones, isophorones, epoxy hardeners, oil modifiers, fumed silicas, matting agents, TAA compounds, and acetylenic diol-based surfactants, which find use in consumer products and various industrial applications. In the Nutrition & Care division, Evonik provides compounds like amphoteric surfactants, ceramides, phytosphingosines, oleochemicals, quaternary derivatives, amino acids and their derivatives, synthetic products, pharmaceutical-grade polymers, and DL-methionine. These are crucial for consumer goods, animal nutrition, and healthcare industries. The Smart Materials segment manufactures advanced substances including hydrogen peroxide, peracetic acid, various activated nickel and precious metal catalysts (for powder, oil, and fat hydrogenation), amorphous polyalphaolefins, polybutadienes, polyester resins, thermoplastic and reactive methacrylate resins, PEEK, polyamide 12, organosilanes, chlorosilanes, and different types of silicas (fumed and precipitated). These serve a broad spectrum of industries including automotive, paints, coatings, adhesives, and construction. Through its Performance Materials segment, the company produces polymer materials and intermediate chemicals, including butene-1, DINP, isononanol, cyanuric chloride, alkoxides, and superabsorbents, specifically for the rubber, plastics, and automotive sectors. Lastly, the Technology & Infrastructure segment provides crucial internal services, encompassing site management, utilities and waste disposal, technical expertise, process technology, engineering, and logistics. Evonik maintains a significant international presence, with operations spanning across the Asia-Pacific region, Europe, the Middle East, Africa, Central and South America, and North America. Founded in 1873, the firm's main offices are located in Essen, Germany, and it functions as a subsidiary of RAG-Stiftung.
No mergers or acquisitions recorded for this company.
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| -2.23% | +1.68% | +2.28% | +10.53% | +24.33% | +31.80% | -10.42% | -10.74% | -40.37% | -39.00% | -46.78% |
Revenue flow
Revenue by geography
Revenue by segment
Revenue composition
By product
By geography
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
DCF figures are point estimates: small changes in growth or discount-rate assumptions move them materially. Read them as a reference, not a precise target.
| Rating | 2026-05 | Change |
|---|---|---|
| Strong Buy | 2 | 0 |
| Buy | 3 | 0 |
| Hold | 6 | 0 |
| Sell | 2 | -1 |
| Strong Sell | 1 | 0 |
-
Revenue growth Chemicals - Specialty: +4.7%-7.2% Q1'26: -9.3% (vs Q1'25)
-
EPS growth Chemicals - Specialty: +13.2%+18.8% ★ Q1'26: -46.0% (vs Q1'25)
-
FCF margin FCF growth · Chemicals - Specialty: +44.1%+3.5% Q1'26: +4.6% (vs Q1'25)
-
EBIT margin Chemicals - Specialty: +8.8%+4.6% Q1'26: +7.1% (vs Q1'25)
-
ROIC Chemicals - Specialty: +5.6%+3.7% Q1'26: +8.2% (vs Q1'25)
-
Share dilution Chemicals - Specialty: +0.1%+0.0% Q1'26: +0.0% (vs Q1'25)
-
Debt / EBITDA Net debt/EBITDA · Chemicals - Specialty: 0.18×2.10× Q1'26: 0.70× (vs Q1'25)
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
| Metric |
Dec 2013 actual |
Dec 2014 actual |
Dec 2015 actual |
Dec 2016 actual |
Dec 2017 actual |
Dec 2018 actual |
Dec 2019 actual |
Dec 2020 actual |
Dec 2021 actual |
Dec 2022 actual |
Dec 2023 actual |
Dec 2024 actual |
Dec 2025 actual |
Dec 2026 13 Rev. Ana. 10 EPS Ana. |
Dec 2027 13 Rev. Ana. 11 EPS Ana. |
Dec 2028 8 Rev. Ana. 5 EPS Ana. |
Dec 2029 7 Rev. Ana. 1 EPS Ana. |
Dec 2030 7 Rev. Ana. 1 EPS Ana. |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue |
12.87B
est: 13.08B (-1.5%)
|
12.92B
est: 13.10B (-1.4%)
|
13.51B
est: 13.66B (-1.2%)
|
12.73B
est: 12.59B (+1.1%)
|
14.42B
est: 14.41B (+0.0%)
|
15.02B
est: 14.98B (+0.3%)
|
13.11B
est: 13.06B (+0.4%)
|
12.20B
est: 12.12B (+0.6%)
|
14.96B
est: 14.61B (+2.4%)
|
18.49B
est: 18.36B (+0.7%)
|
15.27B
est: 15.10B (+1.1%)
|
15.16B
est: 15.13B (+0.2%)
|
14.07B
est: 14.05B (+0.1%)
|
14.42B
13.76B – 15.49B
+2.6% YoY
|
14.58B
13.86B – 15.24B
+1.1% YoY
|
14.96B
14.95B – 14.97B
+2.6% YoY
|
15.07B
14.35B – 15.97B
+0.7% YoY
|
16.03B
15.26B – 16.99B
+6.4% YoY
|
| EBITDA |
1.74B
est: 1.53B (+13.8%)
|
1.95B
est: 2.67B (-27.0%)
|
2.45B
est: 1.38B (+77.6%)
|
1.94B
est: 1.84B (+5.1%)
|
1.99B
est: 2.07B (-3.9%)
|
1.84B
est: 1.83B (+0.8%)
|
2.02B
est: 1.55B (+30.5%)
|
1.76B
est: 2.97B (-40.8%)
|
2.18B
est: 3.13B (-30.4%)
|
2.07B
est: 3.24B (-36.1%)
|
991.00M
est: 1.72B (-42.5%)
|
1.76B
est: 3.58B (-50.8%)
|
1.84B
est: 1.60B (+15.0%)
|
1.64B
1.57B – 1.77B
+2.6% YoY
|
1.66B
1.58B – 1.74B
+1.1% YoY
|
1.71B
1.70B – 1.71B
+2.6% YoY
|
1.72B
1.64B – 1.82B
+0.7% YoY
|
1.83B
1.74B – 1.94B
+6.4% YoY
|
| EBIT |
1.10B
est: 596.99M (+84.1%)
|
1.13B
est: 1.05B (+8.0%)
|
1.69B
est: 1.14B (+47.8%)
|
1.23B
est: 1.54B (-20.0%)
|
1.36B
est: 1.48B (-8.2%)
|
1.01B
est: 1.27B (-21.0%)
|
1.07B
est: 916.73M (+16.7%)
|
763.00M
est: 1.02B (-24.9%)
|
1.16B
est: 1.07B (+8.2%)
|
974.00M
est: 1.11B (-12.1%)
|
-107.00M
est: 637.96M (-116.8%)
|
646.00M
est: 639.55M (+1.0%)
|
640.00M
est: 593.59M (+7.8%)
|
609.17M
581.10M – 654.49M
+2.6% YoY
|
616.05M
585.58M – 643.98M
+1.1% YoY
|
631.97M
631.40M – 632.55M
+2.6% YoY
|
636.59M
606.18M – 674.66M
+0.7% YoY
|
677.12M
644.77M – 717.61M
+6.4% YoY
|
| Net Income |
2.05B
est: 834.53M (+146.1%)
|
568.00M
est: 2.06B (-72.4%)
|
991.00M
est: 601.68M (+64.7%)
|
844.00M
est: 914.34M (-7.7%)
|
717.00M
est: 963.11M (-25.6%)
|
932.00M
est: 741.93M (+25.6%)
|
774.00M
est: 814.48M (-5.0%)
|
465.00M
est: 1.97B (-76.4%)
|
746.00M
est: 2.08B (-64.1%)
|
540.00M
est: -295.00M (+283.1%)
|
-465.00M
est: -90.00M (-416.7%)
|
222.00M
est: 739.33M (-70.0%)
|
265.00M
est: 596.84M (-55.6%)
|
670.61M
511.40M – 829.82M
+12.4% YoY
|
662.32M
558.99M – 765.64M
-1.2% YoY
|
773.49M
623.33M – 923.66M
+16.8% YoY
|
697.66M
654.33M – 751.90M
-9.8% YoY
|
786.95M
738.08M – 848.13M
+12.8% YoY
|
| SGA |
1.93B
est: 2.05B (-6.2%)
|
1.89B
est: 1.93B (-2.0%)
|
2.14B
est: 2.00B (+6.9%)
|
2.20B
est: 1.97B (+11.5%)
|
2.43B
est: 2.51B (-3.4%)
|
2.41B
est: 2.51B (-3.9%)
|
2.08B
est: 1.89B (+10.0%)
|
2.00B
est: 1.94B (+2.9%)
|
2.26B
est: 2.05B (+10.5%)
|
2.59B
est: 2.12B (+22.0%)
|
2.33B
est: 2.35B (-0.7%)
|
2.67B
est: 2.34B (+14.0%)
|
2.21B
est: 2.19B (+1.3%)
|
2.24B
2.14B – 2.41B
+2.6% YoY
|
2.27B
2.16B – 2.37B
+1.1% YoY
|
2.33B
2.33B – 2.33B
+2.6% YoY
|
2.34B
2.23B – 2.48B
+0.7% YoY
|
2.49B
2.37B – 2.64B
+6.4% YoY
|
| EPS |
4.41
est: 1.79 (+146.3%)
|
1.22
est: 1.56 (-21.6%)
|
2.13
est: 2.33 (-8.6%)
|
1.81
est: 1.89 (-4.1%)
|
1.53
est: 2.10 (-27.3%)
|
2.00
est: 2.56 (-21.9%)
|
1.66
est: 1.84 (-9.7%)
|
1.06
est: 1.37 (-22.8%)
|
1.60
est: 1.98 (-19.3%)
|
1.16
est: 2.26 (-48.7%)
|
-1.00
est: -0.19 (-421.8%)
|
0.48
est: 1.57 (-69.5%)
|
0.57
est: 1.27 (-55.1%)
|
1.31
1.10 – 1.78
+3.0% YoY
|
1.37
1.20 – 1.64
+4.6% YoY
|
1.52
1.34 – 1.98
+10.9% YoY
|
1.50
1.40 – 1.61
-1.3% YoY
|
1.69
1.58 – 1.82
+12.8% YoY
|
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-08 | B+ | 3/5 | 5/5 | 3/5 | 4/5 | 1/5 | 2/5 | 4/5 |
| 2026-05-07 | B+ | 3/5 | 5/5 | 3/5 | 4/5 | 1/5 | 2/5 | 4/5 |
| 2026-05-06 | B+ | 3/5 | 5/5 | 3/5 | 4/5 | 1/5 | 2/5 | 4/5 |
| 2026-05-05 | B+ | 3/5 | 5/5 | 3/5 | 4/5 | 1/5 | 2/5 | 4/5 |
| 2026-05-04 | B+ | 3/5 | 5/5 | 3/5 | 4/5 | 1/5 | 2/5 | 4/5 |
| 2026-04-30 | B+ | 3/5 | 5/5 | 3/5 | 4/5 | 1/5 | 2/5 | 4/5 |
| 2026-04-29 | A- | 4/5 | 5/5 | 3/5 | 5/5 | 1/5 | 2/5 | 4/5 |
| 2026-04-28 | A- | 4/5 | 5/5 | 3/5 | 5/5 | 1/5 | 2/5 | 4/5 |
| 2026-04-27 | A- | 4/5 | 5/5 | 3/5 | 5/5 | 1/5 | 2/5 | 4/5 |
| 2026-04-24 | A- | 4/5 | 5/5 | 3/5 | 5/5 | 1/5 | 2/5 | 4/5 |
| 2026-04-23 | A- | 4/5 | 5/5 | 3/5 | 5/5 | 1/5 | 2/5 | 4/5 |
| 2026-04-22 | A- | 4/5 | 5/5 | 3/5 | 5/5 | 1/5 | 2/5 | 4/5 |
| 2026-04-21 | A- | 4/5 | 5/5 | 3/5 | 5/5 | 1/5 | 2/5 | 4/5 |
| 2026-04-20 | A- | 4/5 | 5/5 | 3/5 | 5/5 | 1/5 | 2/5 | 4/5 |
| 2026-04-17 | A- | 4/5 | 5/5 | 3/5 | 5/5 | 1/5 | 2/5 | 4/5 |
| 2026-04-16 | A- | 4/5 | 5/5 | 3/5 | 5/5 | 1/5 | 2/5 | 4/5 |
| 2026-04-15 | A- | 4/5 | 5/5 | 3/5 | 5/5 | 1/5 | 2/5 | 4/5 |
Owner Earnings
Ownership Overview
Ownership breakdown not available.
No beneficial ownership filings recorded.
Institutional Activity (13F)
Institutional history not available.
Top holders not available.
Insider Activity
No insider activity available.
Insider history not available.
No recent insider transactions.
Executive team
Executive compensation
Executive compensation not available.
No CEO compensation history available.
Proxy statements
No proxy statements available for this company yet.
Recent SEC filings
No SEC filings available for this company yet.
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Christian Kullmann | CEO, CFO & Chairman of the Executive Board | 3M | male |
| Thomas Wessel | Chief Human Resources Officer, Labor Relations Director & Member of Executive Board | 2M | male |
| Lauren Kjeldsen | Chief Operating Officer of Custom Solutions & Member of the Management Board | 1M | female |
| Claudine Mollenkopf | Chief Operating Officer of Advanced Technologies & Member of the Management Board | 1M | — |
| Thomas Mahlstedt | Vice President M&A, Corporate Legal & Compliance | — | male |
| Tim Lange | Head of Investor Relations | — | male |
| Wilfried Ostendorf | Head of Production and Technology | — | — |
| Christian Schmid | Head of Corporate Communications | — | male |
| Matthias Ruch | Head of External Communications & Corporate Press Officer | — | male |
| Stefan Mack | Head of the Methionine & Derivatives Product Line | — | — |
No data available for this company.
No Senate trading activity found for this company.
No House trading activity found for this company.
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for EVK.DE
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
